A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Completed · Phase 1
Conditions studied: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
In brief
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel combination
Key facts
- Study ID
- NCT02051751
- Run by
- Novartis Pharmaceuticals
- People needed
- 19
- Starts
- 2014-03-05
- Expected to finish
- 2016-08-19
- Last updated by the study team
- 2020-12-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology Group — Fayetteville, Arkansas, United States
- Horizon Oncology Center BioAdvance — Lafayette, Indiana, United States
- Novartis Investigative Site — Toulouse, France
- Novartis Investigative Site — Milan, MI, Italy
- Novartis Investigative Site — Barcelona, Catalonia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.